Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Karnofsky Performance Status

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    696 result(s) found for: Karnofsky Performance Status. Displaying page 1 of 35.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-000173-21 Sponsor Protocol Number: (no code number allocated) Start Date*: 2005-11-28
    Sponsor Name:Dieter Hoelzer, MD,PhD
    Full Title: A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCYTE® (CYTARABINE LIPOSOME INJECTION) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR H...
    Medical condition: Acute lymphoblastic leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017295-24 Sponsor Protocol Number: 997262001 Start Date*: 2010-03-10
    Sponsor Name:University Hospital Motol
    Full Title: Phase I/II clinical trial:Immunotherapy of hormone-refractory prostate cancer patients with dendritic cell-based vaccine (Fáze I/II klinické studie imunoterapie hormonálně refrakterního karcinomu p...
    Medical condition: Patients with hormone-refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017259-91 Sponsor Protocol Number: 997262002 Start Date*: 2010-03-10
    Sponsor Name:University Hospital Motol
    Full Title: Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine
    Medical condition: Patients with prostate cancer in the stage of biochemical relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000304-14 Sponsor Protocol Number: GlioVax Start Date*: 2018-03-06
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma
    Medical condition: newly diagnosed glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003100-11 Sponsor Protocol Number: OSAG 101-BSC-05 Start Date*: 2006-02-14
    Sponsor Name:Oncoscience AG
    Full Title: Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents
    Medical condition: Newly diagnosed pontine glioma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005874-24 Sponsor Protocol Number: PEI004/2021 Start Date*: 2022-07-01
    Sponsor Name:Juan Enrique Domínguez Muñoz
    Full Title: Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer
    Medical condition: pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006143-26 Sponsor Protocol Number: 2019/ABM/01/00062 Start Date*: 2021-05-02
    Sponsor Name:Śląski Uniwersytet Medyczny w Katowicach
    Full Title: A Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Pa...
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004516-21 Sponsor Protocol Number: IMMU-107-04 Start Date*: 2014-09-16
    Sponsor Name:Immunomedics, Inc.
    Full Title: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastat...
    Medical condition: Metastatic (Stage IV) Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Prematurely Ended) FR (Completed) PL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003272-38 Sponsor Protocol Number: TPU-S1204 Start Date*: Information not available in EudraCT
    Sponsor Name:Taiho Pharma USA, Inc
    Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, TWO-STAGE, PHASE 2 STUDY OF S-1 IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER.
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000963-81 Sponsor Protocol Number: PM0259CA221B0 Start Date*: 2004-11-15
    Sponsor Name:Robapharm AG
    Full Title: A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines
    Medical condition: Treatment in metastatic breast cancer previously treated with anthracyclines
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001504-37 Sponsor Protocol Number: 30/2006/O/Sper Start Date*: 2006-05-18
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS ACHN-IL2 MIXED TO AUTOLOGOUS TUMOR CELLS CT-AUT IN PATIENTS WITH METASTATIC RENAL CARCINOMA.
    Medical condition: Metastatic Kidney Cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050018 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001499-10 Sponsor Protocol Number: CO34 Start Date*: 2005-05-19
    Sponsor Name:Dr. José Ramón Mel Lorenzo
    Full Title: 'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients' Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en...
    Medical condition: Advanced Breast Cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005253-22 Sponsor Protocol Number: 1216.10 Start Date*: 2006-07-24
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-...
    Medical condition: patients with unresectable (locally advanced or metastatic) pancreatic cancer, either chemonaive or after first-line chemotherapy with a gemciatbine based regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000364-30 Sponsor Protocol Number: I4T-MC-JVDA Start Date*: 2021-06-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
    Medical condition: Pediatric Solid Tumor CNS Malignancies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003813-15 Sponsor Protocol Number: CONKO-005 Start Date*: 2007-11-26
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie
    Medical condition: pancreatic cancer adjuvant therapy after R0-resection Gemcitabine plus Erlotinib vs. Gemcitabine mono, given over 24 weeks randomised trial
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000725-41 Sponsor Protocol Number: CLI-107-15 Start Date*: 2013-01-22
    Sponsor Name:Cytheris S.A.
    Full Title: A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy.
    Medical condition: HIV-infected patients with Progressive Multifocal Leukoencephalopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10036807 Progressive multifocal leukoencephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001363-22 Sponsor Protocol Number: TH-CR-302 Start Date*: 2004-12-10
    Sponsor Name:Threshold Pharmaceuticals
    Full Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
    Medical condition: Previously treated metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10033599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002082-13 Sponsor Protocol Number: BUF-17/RAP Start Date*: 2008-07-09
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Randomised, double-blind, placebo-controlled, multicentre, comparative phase II pilot study on the efficacy and tolerability of an 8-week rectal treatment with 2 mg budesonide or placebo for the pr...
    Medical condition: prevention of acute radiation proctitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037766 Radiation proctitis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005182-66 Sponsor Protocol Number: A4091029 Start Date*: 2009-05-04
    Sponsor Name:Pfizer Inc 235 East 42nd Street New York, NY 10017
    Full Title: PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES
    Medical condition: PAIN DUE TO BONE METASTASES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006370-25 Sponsor Protocol Number: IMA901-202 Start Date*: 2007-05-07
    Sponsor Name:immatics biotechnologies GmbH
    Full Title: Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurabl...
    Medical condition: HLA-A*02-positive patients with advanced clear cell RCC who have progressed during or after first-line systemic therapy for advanced disease and have a favourable or intermediate risk after systemi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) GB (Completed) AT (Completed) HU (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 17 04:13:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA